Skip to main content
. 2019 Apr 14;25:2745–2755. doi: 10.12659/MSM.913420

Figure 5.

Figure 5

CDK6 is a direct target of miR-641. (A) Putative binding site of miR-641 on CDK6 and the mutation in the predicted seed region. Dual-luciferase reporter assays were used to assess H1299 cells (B, C) and SPC-A1 cells (D, E) co-transfected with CDK6-WT or CDK6-MUT and miR-NC mimics, miR-641 mimics, miR-NC inhibitors, or miR-641 inhibitors. miR-NC mimics, miR-641 mimics, miR-NC inhibitors, or miR-641 inhibitors were transfected into H1299 cells (F) and SPC-A1 cells (G), followed by determination of CDK6 protein level by Western blot analysis. qRT-PCR assay of CDK6 expression in NSCLC tissues and normal tissues (H), NSCLC cell lines and 16HBE (I). (J) The correlation between CRNDE and miR-641 expression was assessed in NSCLC tissues. * P<0.05 vs. respective control.